Inhibition of the TCF12/VSIG4 axis by palbociclib diminishes the proliferation and migration of glioma cells and decreases the M2 polarization of glioma‐associated microglia
Drug Development Research · 2024-08 · 85 (5)
DOI: 10.1002/ddr.22230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 05.07.2024. Verfasst von Chuankun Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Glioma, Cell Movement, Piperazines, Pyridines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
The CDK4/CDK6 inhibitor palbociclib has shown the encouraging promise in the treatment of glioma. Here, we elucidated how palbociclib exerts suppressive functions in the M2 polarization of glioma‐related microglia and the progression of glioma. Xenograft experiments were used to evaluate the function in vivo. The mRNA levels of transcription factor 12 (TCF12) and VSIG4 were detected by RT‐qPCR, and their protein levels were assessed by immunoblotting. Cell migration was tested by wound‐healing assay. Cell cycle distribution and M1/M2 microglia phenotype analysis were performed by flow cytometry. The levels of IFN‐γ, TNF‐α, IL‐6,and TGF‐β were measured by ELISA. The TCF12/VSIG4 association was verified by luciferase reporter and chromatin immunoprecipitation (ChIP) assays. In U251 and LN229 glioma cells, TCF12 and VSIG4 were overexpressed, and palbociclib reduced their expression levels. TCF12 upregulation enhanced the proliferation and migration of glioma cells and the M2 polarization of glioma‐associated microglia in vitro as well as the tumorigenicity of U251 glioma cells in vivo, which could be reversed by palbociclib. Mechanistically, TCF12 could enhance VSIG4 transcription and expression by binding to the VSIG4 promoter. TCF12 deficiency led to repression in glioma cell proliferation and migration as well as microglia M2 polarization, which could be abolished by increased VSIG4 expression. Our study reveals the novel TCF12/VSIG4 axis responsible for the efficacy of palbociclib in combating glioma, offering a rationale for the application of palbociclib in glioma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Medical Imaging, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Haitao Jiang
Zitieren
APA
Li, C., Li, R., Wang, Y., & Jiang, H. (2024). Inhibition of the TCF12/VSIG4 axis by palbociclib diminishes the proliferation and migration of glioma cells and decreases the M2 polarization of glioma‐associated microglia. Drug Development Research, 85(5). https://doi.org/10.1002/ddr.22230
Vancouver
Li C, Li R, Wang Y, Jiang H. Inhibition of the TCF12/VSIG4 axis by palbociclib diminishes the proliferation and migration of glioma cells and decreases the M2 polarization of glioma‐associated microglia. Drug Development Research. 2024;85(5). doi:10.1002/ddr.22230
BibTeX
@article{Li2024,
author = {Li, Chuankun and Li, Ruichun and Wang, Yuan and Jiang, Haitao},
title = {Inhibition of the TCF12/VSIG4 axis by palbociclib diminishes the proliferation and migration of glioma cells and decreases the M2 polarization of glioma‐associated microglia},
journal = {Drug Development Research},
year = {2024},
volume = {85},
number = {5},
doi = {10.1002/ddr.22230}
}
EUVIMED